The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes.

1999 Feb;90(2):238-46. Unique Identifier : AIDSLINE MED/99180796
Plaeger S; Bass HZ; Nishanian P; Thomas J; Aziz N; Detels R; King J; Cumberland W; Kemeny M; Fahey JL; Center for Interdisciplinary Research in Immunology and Disease; (CIRID) and the Jonsson Comprehensive Cancer Center, UCLA School; of Medicine, Los Angeles, California, 90095, USA.

Abstract: One hundred and eighteen HIV-infected homosexual men without AIDS and 40 control seronegative homosexual men were assessed for 23 parameters reflecting immune activation to determine prognostic significance for occurrence of AIDS. Samples cryopreserved in 1987-1989 were analyzed, with AIDS occurrence determined by mid-1992. Cell surface antigens assessed on the major lymphocyte subsets were HLA-DR, CD38, CD71, and CD25. Soluble serum molecules assessed were tumor necrosis factor alpha, soluble TNFalpha receptor II, soluble IL-2 receptor alpha, neopterin, and beta2-microglobulin. Using a proportional hazards model, prognostic markers included decreased CD4 number and percentage; increased sIL-2R, neopterin, and beta2M; increased percentage HLA-DR+ total lymphocytes and CD4+ cells; increased CD38+ total lymphocytes and CD8+ cells; increased CD71+ total lymphocytes and CD4+ cells; and decreased CD25+ total lymphocytes and CD19+ cells. After adjustment for CD4 cell levels, sIL-2R, neopterin, beta2M, and CD25+ CD19 cells remained significant, indicating that additional information about AIDS risk was provided by these markers. Copyright 1999 Academic Press.

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/ETIOLOGY/IMMUNOLOGY Adult Antigens, CD/METABOLISM Antigens, Differentiation/METABOLISM Antigens, Differentiation, B-Lymphocyte/METABOLISM Antigens, Surface/*METABOLISM Biological Markers/BLOOD Case-Control Studies CD4 Lymphocyte Count Homosexuality Human HIV Infections/BLOOD/*IMMUNOLOGY HIV Seronegativity/IMMUNOLOGY HLA-DR Antigens/METABOLISM *Lymphocyte Transformation Lymphocytes/*IMMUNOLOGY Male Middle Age NAD+ Nucleosidase/METABOLISM Prognosis Proportional Hazards Models Receptors, Interleukin-2/METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.
990630
A9960946

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .